| Website | agendia.com |
| Category | BioTech |
| Phone | +31 20 462 1500 |
| Employees | |
| Founded | 2003 |
| Description | biotechnology company |
| Total | $57M |
| Series D, 8/07 Van Herk Biotech Gilde Healthcare Partners Global Life Science Ventures | $34M |
| Series E, 9/09 ING Group Van Herk Biotech Gilde Healthcare Partners Global Life Science Ventures | $23M |
Agendia’s molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans.
MammaPrint®, Agendia’s main product for breast cancer, analyzes tumors based on a 70 gene signature and offers innovative, unbiased and clinically significant insight into tumor biology. It is the first FDA cleared breast cancer gene profiling assay of its kind and provides a highly accurate determination of metastasis risk (low or high) and distant recurrence within 10 years.
